Document Type : Original Article
Authors
1
Laboratoire de Recherche Clinique et Système de Santé, Université André Salifou, Zinder, Niger
2
Département de Médecine, Faculté des Sciences de Santé, Université André Salifou, Zinder, Niger
3
Laboratoire National de Reference sur la Resistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger
4
Département de Médecine, Faculté des Sciences de santé, Université Abdou Moumouni, Niamey, Niger
5
Département de Médicine, Hôpital National Amirou Boubacar Diallo, Niamey, Niger
6
Département de Médecine, Hôpital National de Zinder, Zinder, Niger
Abstract
Background: Multidrug-resistant (MDR) bacteria significantly threaten public health globally. In recent years, new molecules such as tigecycline have been introduced to combat these MDR bacteria. This study aimed to assess the in vitro activity of tigecycline against MDR bacteria in Niger. Methods: A cross-sectional study was conducted at the National Reference Laboratory for Antimicrobial Resistance (NRL-AMR) on multidrug-resistant (MDR) isolates from pathological samples. The isolates were tested in vitro with tigecycline using the agar diffusion method (Kirby–Bauer) according to the EUCAST 2024 recommendations. Results: A total of 312 MDR bacterial isolates were included: 198 ESBL, 14 CRAB, 27 CRPA, 26 MRSA, and 47 CRE. The in vitro test with tigecycline showed a sensitivity of 83.01% with a resistance rate of 16.99%. A resistance rate of 100% was found in CRPA, followed by CRAB (35.71%), CRE (14.90%), and ESBL (7.09%), with a sensitivity rate of 100% for MRSA isolates. Conclusion: Although tigecycline has shown good results against clinical MRSA, ESBL, and CRE isolates, the emergence of tigecycline-resistant isolates has been observed, which might seem alarming. We suggest exploring a combination therapy of tigecycline with cefiderecol or colistin as a potential treatment option against CRAB and CRPA infections in Niger.
Keywords
Main Subjects
)
View on SCiNiTO